Beyond the expression of PD-1/PD-L1, there are several other clinically useful predictors of responses to immune checkpoint inhibition, most notably a high microsatellite instability phenotype (MSI-H) and/or an increased tumor mutation burden (TMB). Here, CD274 is linked to neoplasm.